Delhi high court to hear central bank challenge to CIC order seeking information on defaults by top industrialists The Reserve Bank of India (RBI) has challenged an order by the Central Information Commission (CIC) asking the central bank to disclose names of the top 100 industrialists who have defaulted on loan repayments. In a writ petition to the Delhi high court, which is scheduled to be heard on 29 May, the central...

-The Times of India Marks obtained by a student in the Class X CBSE exams cannot be revealed under the Right to Information (RTI) Act as it would defeat the very purpose of the new grading system, the Delhi high court has ruled. Setting aside a ruling by the Central information Commission asking the Central Board of Secondary Education to reveal marks obtained by a girl in her Class X board examination...

-The Economic Times   The Centre's interlocutors panel on Jammu and Kashmir has recommended setting up of a constitutional committee to review all central Acts and Articles of the Constitution extended to Jammu and Kashmir. The purpose is to determine how the application of these laws has dented the special status of J&K and curtailed the state government's powers to cater to welfare of its people.  The report of the interlocutors - Dileep...

The Parliament of India, the highest citadel of its democracy, recently completed 60 years. This magnificent circular edifice was inaugurated on January 18, 1927, by the then governor-general, Lord Irwin, and legislative councils had conducted its sessions here. After Independence, the Central Hall accommodated the Constituent Assembly till it completed writing the Constitution. The first Lok Sabha was constituted on April 17, 1952, and the first Rajya Sabha on April...

German drugmaker Bayer AG has demanded the withdrawal of the country's first compulsory licence given to Natco Pharma, arguing that a three-fourth reduction in the price of the anti-cancer drug by another Indian firm has made the permit redundant and its patent itself is vulnerable to being revoked. In March, India allowed Natco Pharma to legally make and sell a low-cost version of cancer drug Nexavar at 3% of the original...